Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

641 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma.
Hoffmann F, Zarbl R, Niebel D, Sirokay J, Fröhlich A, Posch C, Holderried TAW, Brossart P, Saavedra G, Kuster P, Strieth S, Gielen GH, Ring SS, Dietrich J, Pietsch T, Flatz L, Kristiansen G, Landsberg J, Dietrich D. Hoffmann F, et al. Among authors: kristiansen g. Clin Epigenetics. 2020 Jun 26;12(1):94. doi: 10.1186/s13148-020-00883-9. Clin Epigenetics. 2020. PMID: 32586358 Free PMC article.
Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma.
Fröhlich A, Sirokay J, Fietz S, Vogt TJ, Dietrich J, Zarbl R, Florin M, Kuster P, Saavedra G, Valladolid SR, Hoffmann F, Flatz L, Ring SS, Golletz C, Pietsch T, Strieth S, Brossart P, Gielen GH, Kristiansen G, Bootz F, Landsberg J, Dietrich D. Fröhlich A, et al. Among authors: kristiansen g. EBioMedicine. 2020 Sep;59:102962. doi: 10.1016/j.ebiom.2020.102962. Epub 2020 Aug 30. EBioMedicine. 2020. PMID: 32861198 Free PMC article.
CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab).
Fietz S, Zarbl R, Niebel D, Posch C, Brossart P, Gielen GH, Strieth S, Pietsch T, Kristiansen G, Bootz F, Landsberg J, Dietrich D. Fietz S, et al. Among authors: kristiansen g. Cancer Immunol Immunother. 2021 Jun;70(6):1781-1788. doi: 10.1007/s00262-020-02777-4. Epub 2020 Nov 16. Cancer Immunol Immunother. 2021. PMID: 33196890 Free PMC article.
No evidence to support the impact of migration background on treatment response rates and cancer survival: a retrospective matched-pair analysis in Germany.
Rüdiger R, Geiser F, Ritter M, Brossart P, Keyver-Paik MD, Faridi A, Vatter H, Bootz F, Landsberg J, Kalff JC, Herrlinger U, Kristiansen G, Pietsch T, Aretz S, Thomas D, Radbruch L, Kramer FJ, Strassburg CP, Gonzalez-Carmona M, Skowasch D, Essler M, Schmid M, Nadal J, Ernstmann N, Sharma A, Funke B, Schmidt-Wolf IGH. Rüdiger R, et al. Among authors: kristiansen g. BMC Cancer. 2021 May 10;21(1):526. doi: 10.1186/s12885-021-08141-8. BMC Cancer. 2021. PMID: 33971845 Free PMC article.
Melanoma Brain Metastases Patient-Derived Organoids: An In Vitro Platform for Drug Screening.
Abedellatif SE, Hosni R, Waha A, Gielen GH, Banat M, Hamed M, Güresir E, Fröhlich A, Sirokay J, Wulf AL, Kristiansen G, Pietsch T, Vatter H, Hölzel M, Schneider M, Toma MI. Abedellatif SE, et al. Among authors: kristiansen g. Pharmaceutics. 2024 Aug 5;16(8):1042. doi: 10.3390/pharmaceutics16081042. Pharmaceutics. 2024. PMID: 39204387 Free PMC article.
Cell-Free SHOX2 DNA Methylation in Blood as a Molecular Staging Parameter for Risk Stratification in Renal Cell Carcinoma Patients: A Prospective Observational Cohort Study.
Jung M, Ellinger J, Gevensleben H, Syring I, Lüders C, de Vos L, Pützer S, Bootz F, Landsberg J, Kristiansen G, Dietrich D. Jung M, et al. Among authors: kristiansen g. Clin Chem. 2019 Apr;65(4):559-568. doi: 10.1373/clinchem.2018.297549. Epub 2019 Jan 9. Clin Chem. 2019. PMID: 30626634
641 results